PT Darya-Varia Laboratoria Tbk (DVLA) Fair Value & Analysis
Healthcare · ID · Market cap 1.6T IDR
Fair value as of: Jun 24, 2026
Analysis
PT Darya-Varia Laboratoria Tbk (DVLA) currently trades at 1,565 IDR, while our model-based Fair Value estimate is 2,847 IDR — implying the stock looks roughly 81.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
PT Darya-Varia Laboratoria Tbk manufactures and trades pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Consumer Health Products, Prescription Drugs, Export & Toll Manufacturing, and Services. The company offers consumer health products, including skin nutrition products under the Natur-E brand; respiratory products under the Decolgen, ALLERIN EXPECTORANT, Decolsin, NEOZEP, STOP COLD, SILEX, and HERBABLEND brands for nasal congestion, cough, and breathing issues caused by allergy; multivitamins under the Enervon-C, Enervon Active, Enervon Gold, and Supertin brands; vitamin C under the Vicee brand; supplement for kids with Zinc and vitamin C under the Imunped brand; Biogesic for various types of pain; Diatabs, a anti diarrhea product; and New Enzyplex to prevent indigestion. It also provides prescription products for various therapeutic areas, including cardiology, analgesics, gastro-hepatology, dermamedic, somatic, cough and cold, antibiotic, women h…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is PT Darya-Varia Laboratoria Tbk (DVLA) undervalued?
What is the fair value of DVLA?
What is the quality score of DVLA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.